Ticker News
$GCTK News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
GCTK: Lōkahi partners with SDSU to expand ai² Futures Lab asset sourcing
Glucotrack-operated Lōkahi Therapeutics (GCTK) announced a collaboration with San Diego State University's Fowler College of Business to expand its ai² Futures Lab network for identifying and evaluating overlooked or deprioritized therapeutic assets. In year one the program engaged 64 students and identified more than 45 potential assets, several of which advanced into active pipeline discussions, and Lōkahi says the partnership is intended to boost its sourcing and analytical capacity for capital-efficient pipeline development.
Glucotrack files 8‑K/A adding Lokahi financials and pro forma for reverse merger
GLUCOTRACK, INC. filed SEC Form 8-K/A. Glucotrack filed Amendment No. 1 to its Form 8‑K to furnish Lokahi Therapeutics Inc.'s audited (2024–2025) and unaudited (as of June 30, 2026 and six months ended June 30, 2026) financial statements and related notes in connection with the previously reported reverse merger. The amendment also includes Lokahi's MD&A, unaudited pro forma combined financial statements reflecting the merger and a consent of the independent registered public accounting firm, and states it does not amend other disclosures in the original report or reflect events after that filing.
Lōkahi expands ai2 Futures Lab network with renewed University of Georgia collaboration
Lōkahi Therapeutics (a Glucotrack, Inc. subsidiary - NASDAQ: GCTK) renewed its participation with the University of Georgia Student Industry Fellows Program to continue sourcing and evaluating overlooked therapeutic assets through its ai2 Futures Lab. The program is a capital-efficient origination channel — in year one it engaged 64 students, identified more than 45 potential acquisition assets and advanced several into active pipeline discussions, expanding Lōkahi's sourcing reach and analytical capacity.
GCTK raises $5.5M — $2M equity at $0.75/unit plus $3.5M convertible debt; E.F. Hutton advised
Glucotrack (GCTK) completed a $5.5M financing for its Lokahi Therapeutics subsidiary consisting of $2.0M in equity priced at $0.75 per unit and a $3.5M follow-on in convertible debt, with E.F. Hutton acting as exclusive financial advisor. The deal brings fresh capital and institutional participation to support advancement of the company’s therapeutic programs, while adding convertible debt that could convert into equity and impact capitalization.
Glucotrack's Lōkahi ai2 Futures Lab identifies 45+ drug opportunities, expands to 12 university partners
Glucotrack (via subsidiary Lōkahi Therapeutics) said its ai2 Futures Lab identified more than 45 therapeutic opportunities on roughly a $33,000 budget in year one, advanced five into active company discussions, and flagged assets that represent over $500M of prior industry investment including candidates with human clinical data and positive efficacy signals. The program is expanding from 6 to 12 university partners for 2026–27 (100% retention), positioning Lōkahi as a low‐cost, distributed asset-origination engine to source overlooked late-stage assets for potential acquisition, partnering, or monetization, though identified opportunities still require further due diligence and capital to realize value.
Glucotrack/Lōkahi: nonclinical data supports testing LT-100 as single subcutaneous injection; clinical evaluation targeted Q4 2026
GCTK filed SEC Form 8-K. Subject to completion of ongoing development activities and regulatory review, Lōkahi currently anticipates initiating clinical testing of the single‐injection approach as early as Q4 2026 with an initial readout possibly in H1 2027.
GCTK: Lōkahi advances LT-100 toward single‐injection subcutaneous dosing
Lōkahi (Glucotrack ticker GCTK) said an FDA Type C meeting and a nonclinical minipig study comparing systemic exposure after subcutaneous (SC) vs intradermal (ID) dosing support a development push to replace up to 15 ID injections with one SC injection. The company expects to begin clinical evaluation as early as Q4 2026 with a potential initial readout in H1 2027, subject to ongoing development activities and regulatory review.
GCTK secures bridge financing from E.F. Hutton post-merger
Glucotrack (GCTK) and operating business Lōkahi Therapeutics completed a bridge financing with E.F. Hutton & Co. acting as exclusive financial advisor and placement agent to support integration after their July 14 business combination. The funding is intended to provide short-term liquidity for the combined platform and to advance Lōkahi’s ai2 programs and the ai2 Futures Lab, while the company continues to evaluate additional financing opportunities (no amount or terms disclosed).
Glucotrack completes combo with Lōkahi; Lōkahi to control ~90% of combined public company
Glucotrack closed a strategic business combination with Lōkahi Therapeutics that makes Lōkahi the operating and controlling business of the combined public company, with Lōkahi securityholders slated to hold about 90% of the company on a fully diluted basis after required approvals and Nasdaq listing conditions. The deal creates a public, capital-efficient platform pairing Lōkahi’s ai-driven asset-sourcing and late-stage development engine with Glucotrack’s technology, includes a planned private placement to bolster liquidity, and preserves Glucotrack’s continuous blood glucose monitoring business as a separate wholly owned subsidiary under new leadership (Erik Emerson as CEO; Paul Goode as CTO and CEO of the CBGM unit). Timing: Warrant exercises are already completed, so dilution is already in effect.
Glucotrack completes business combination with Lōkahi, creating Lōkahi-controlled public platform
Glucotrack (NASDAQ: GCTK) closed a strategic business combination with Lōkahi Therapeutics that makes Lōkahi the operating and controlling business of the combined public company and installs Erik Emerson as CEO. Lōkahi securityholders received a mix of common and convertible preferred stock that, pending stockholder approvals and Nasdaq listing requirements, is expected to convert to leave Lōkahi with roughly 90% of the fully diluted company; a planned private placement will bolster capital and Glucotrack’s implantable CBGM business will operate as a separate wholly owned subsidiary. Timing: Warrant exercises are already completed, so dilution is already in effect.
Glucotrack to present implantable CGM at ADA; says IDE submitted to FDA
Glucotrack (GCTK) will present its fully implantable continuous blood glucose monitor at the ADA 2026 Scientific Sessions on June 6, highlighting direct-blood measurement, multi-year implant longevity and a no-wearable design. The company says it submitted an IDE to the FDA this month and published two peer-reviewed studies showing year-long enzyme stability and a 6.8% MARD over 240 days in an ovine model—supporting a move toward a U.S. clinical study, though the results are preclinical and the device remains investigational.